Prelude Therapeutics Q2 EPS $(0.58) Up From $(5.50) YoY

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.58) per share. This is a 89.45 percent increase over losses of $(5.50) per share from the same period last year.